1 **Title:** Enterovirus D68 epidemic, UK, 2018, was caused by subclades B3 and D1, predominantly 2 in children and adults respectively, with both subclades exhibiting extensive genetic diversity Authors: Hannah C. Howson-Wells, Theocharis Tsoleridis, Izzah Zainuddin, Alexander W. 3 Tarr, William L. Irving, Jonathan K. Ball, Louise Berry, Gemma Clark and C. Patrick McClure 4 5 Affiliations: 6 Nottingham University Hospitals, Nottingham, UK (H.C. Howson-Wells, I. Zainuddin, G. Clark) University of Nottingham, Nottingham, UK (T. Tsoleridis, A.W. Tarr, J.K. Ball, C.P. McClure) 7 8 Nottingham University Hospitals, Nottingham, UK; University of Nottingham, Nottingham, UK 9 (L. Berry, W.L. Irving) Abstract—word count 150 10 Enterovirus D68 (EV-D68) has been recently identified in biennial epidemics coinciding with 11 diagnoses of non-polio acute flaccid paralysis/myelitis (AFP/AFM). We investigated the 12 prevalence, genetic relatedness and associated clinical features of EV-D68 in 194 known EV 13 positive samples from late 2018, UK. EV-D68 was detected in 83 (58%) of the 143 EV positive 14 samples. Sequencing and phylogenetic analysis revealed an extensive genetic diversity, split 15 between subclades B3 (n=50) and D1 (n=33), suggesting epidemiologically unrelated infections. 16 17 B3 predominated in children and younger adults, and D1 in older adults and the elderly (p=0.0009). Clinical presentation indicated causation or exacerbation of respiratory distress in 18 19 91.4% of EV-D68-positive individuals, principally: cough (75.3%), shortness of breath (56.8%), 20 coryza (48.1%), wheeze (46.9%), supplemental oxygen required (46.9%) and fever (38.9%). 21 Clinical features were not distinguished by subclade. Two cases of AFM were observed, one with EV-D68 detectable in the cerebrospinal fluid, otherwise neurological symptoms were rarely 22 23 reported (n=4).

- 24 Keywords: Virology; Enterovirus; Enterovirus 68, Human; EV-D68; Enterovirus 68;
- 25 Epidemiology, Molecular; genotype; Genetic Epidemiology
- 26

27 Address for correspondence:

- 28 C. Patrick McClure, University of Nottingham, West Block, A Floor, Queens Medical Centre,
- 29 Nottingham, NG7 2UH, UK. Phone: +44 115 8231633 e-mail:
- 30 patrick.mcclure@nottingham.ac.uk
- 31
- 32

33 Text—word count 3493

34 Introduction

The Enterovirus (EV) genus within the non-enveloped ssRNA Picornaviridae family 35 includes seven species infecting humans: three rhinovirus species (Rhinovirus A – Rhinovirus C) 36 and four enterovirus species (Enterovirus A- Enterovirus D) (1). These EV species are further 37 divided into distinct serotypes, prefixed with 'A', 'B', 'C' or 'D' to indicate their species 38 39 assignment. Enterovirus infections in humans are caused by in excess of 100 serotypes and manifest as a diverse array of symptoms from asymptomatic infection to respiratory, epidermal, 40 41 gastrointestinal and neurological presentations (2). Globally EV infections represent a considerable burden of morbidity and mortality (2, 3) and they remain the leading cause of viral 42 meningitis worldwide. 43 Since its recent re-emergence, enterovirus D68 (EV-D68) has been associated with 44 biennial (2014, 2016 and 2018) seasonal epidemics of respiratory infections and, more rarely, 45 acute flaccid myelitis (AFM) across Northern America (4-6), with subsequent identification of 46 47 similar patterns globally (7-9). There are limited studies looking at the true burden EV-D68. Multiple contemporary strains of EV-D68 have been associated with neuropathology in mouse 48 49 models following dissemination to the central nervous system (10, 11) with others suggesting this is a universal EV-D68 phenotype including the archetypal 1962 Fermon strain (12). Despite 50 51 its neurotropic nature, EV-D68 is primarily an infection of the respiratory tract and in contrast to many other enterovirus species, transmission is primarily by airborne routes and fomites (13, 14). 52 53 EV-D68 is infrequently found in faeces (15) and is not thought to spread by the faecal-oral route as it is acid labile (2, 16). There are four identified EV-D68 clades, designated A-D, with 54 55 subclades B3 and D1 contemporaneously predominating in global sequence data (8, 17-21).

56	Evidence is emerging to suggest severity of EV-D68 infection is associated with the presence of
57	other co-morbidities (22); these individuals are more likely to present with complications
58	associated with EV-D68 infection. This large retrospective study also highlighted an upsurge in
59	D1 cases in the adult population at a time when B3 and D1 were co-circulating.
60	Serological studies have retrospectively indicated an increasing prevalence of EV-D68
61	since at least 2006 (13, 23, 24), highlighting a growing importance and foothold in the roster of
62	common childhood infections. The detection of enterovirus antibodies in the cerebrospinal fluid
63	(CSF) of patients with an AFM diagnosis (25) provides further evidence to link enterovirus
64	infection and AFM, however EV-D68 RNA is rarely detected in CSF (7, 26-28)
65	Enterovirus infections are now routinely diagnosed by molecular methods and are further
66	sub-typed by neutralization or sequence based methods (2). Sequencing of the VP1 gene,
67	encoding one of four viral capsid proteins, is considered the current diagnostic typing 'gold-
68	standard' (29), rather than the highly conserved 5' untranslated (5' UTR) genomic region due to
69	recombination events observed within this genomic region (30). Perhaps due to the recent re-
70	emergence of EV-D68 after a period of apparent low prevalence [25, 26], many nucleic acid-
71	based diagnostic assays perform relatively poorly in the detection of this subtype [27].
72	This study retrospectively re-screened EV positive samples from patients assessed at a
73	regional UK hospital between September and December 2018, to determine the prevalence,
74	genetic relatedness and clinical characteristics of EV-D68 infection. Two simple, novel EV-D68-
75	specific RT-PCR assays were designed for both qualitative detection and sequencing of the VP1
76	gene. VP1 sequences were compared to the entire EV-D68 global dataset and clinical
77	characteristics audited to assess clade phenotype.
78	Methods

79 Specimens and ethics

80	Original samples previously underwent routine diagnostic testing for EV RNA by
81	Nottingham University Hospitals (NUH) Clinical Microbiology department, East Midlands, UK,
82	between 2nd September and 15th December 2018. This included total nucleic acid (TNA)
83	extraction (bioMérieux TM NucliSENS [®] easyMAG [®] system) in a 50 μ l elution volume and EV
84	RNA detection by the AusDiagnostics Respiratory Viruses (16-well) (REF 20602) and/or Viral
85	8-well (Ref 27093) assays for the High-Plex 24 system (REF 9150). All TNA extracts were
86	subsequently stored at -80°C.
87	To prevent bias on analysis, TNA extracts were deduplicated to ensure only one
88	specimen per patient was included with neurological panel positives preferentially retained. If
89	multiple TNA extracts were available from the same anatomical site, the earliest TNA extract
90	was selected. All available residual TNA extracts of sufficient volume were included here
91	(n=194) and derived from: throat swabs (n=117) and nasopharyngeal aspirates (n=41), swabs
92	from other sites (n=19), CSF (n=7), sputum (n=4), faeces (n=2), bronchiolar lavage (n=2), whole
93	blood $(n=1)$ and endotracheal secretions $(n=1)$. Ethical approval for the use of residual material
94	and association with anonymized patient information was locally approved under the
95	Nottingham Health Science Biobank Research Tissue Bank, REC reference 15/NW/0685.
96	RT-PCR, Primer Design and sequencing
97	cDNA was synthesized and amplified from TNA extracts as previously described (31).
98	Samples were targeted with a generic 5' UTR based assay generating a ~480 bp product as
99	previously described (31, 32), and two novel EV-D68 specific assays: EV-D68 assay primers
100	were designed following alignment of all available complete EV-D68 genomes (n=348)

101 published on Genbank by November 2018 (NCBI:txid42789). Two overlapping amplicons were

- 102 generated to ensure full coverage of the EV-D68 VP1 gene: primers D68_1442F
- 103 (CCCTGATAATACCTTGGATYAGTGG) combined with D68_2267R
- 104 (GCTGARTTAATRCACATAAARGGTAT) and D68_2167F
- 105 (GACACTNCARGCAATGTTYGT) with D68_2762R
- 106 (CCTGTRTTRCAYTTRCAYCTTGCTAT) generated circa 820bp and 600bp products
- 107 respectively. PCR products of expected size were diluted 1:10 in molecular grade water and
- subjected to Sanger sequencing (Source BioScience, UK) with primers D68_2267R and
- 109 D68_2167F as appropriate. Sequence identity was assessed using NCBI Standard Nucleotide
- 110 BLAST (BLASTn) and the Genome Detective online Enterovirus Genotyping Tool (Version 2.9)
- 111 (33). Complete VP1 sequences were uploaded to Genbank under accession numbers MZ576283
- 112 MZ576352.
- 113 Phylogenetic and statistical analyses
- 114 All publicly available complete VP1 sequences were retrieved from Genbank in June
- 115 2021 and aligned with the study sequences using Geneious Prime 2019.2.3. A phylogenetic tree
- 116 was constructed from the alignment in IQTREE2 (34) by the Maximum Likelihood method with
- the GTR+F+I model and 1000 SH-aLRT bootstraps. Clinical features were compared by
- 118 genotype using a binary logistic regression model in GraphPad Prism v.9.2.0.
- 119 **Results**
- 120 Enteroviral epidemiology in Nottingham, UK, Autumn 2018

The AusDiagnostics respiratory virus panel allows for non-specific detection of both
rhinovirus (RV) and enterovirus (non-differentiated dual target: RV/EV), and specific detection
of EV, in TNA. Detection of RV/EV and EV in respiratory specimens increased from week 36 of
2018 (early September) and EV diagnoses remained elevated until week 45 (November, Figure

125	1). RV/EV numbers remained high after the decline in EV, as had been seen for the
126	corresponding period of 2017 (data not shown). Retrospective analysis of EV positive TNA was
127	performed on samples received for routine testing during this peak period of 2018, between
128	weeks 36 and 50 inclusively. In total, 308 positive patients were identified, of which 194 residual
129	TNA extracts had sufficient volume for further analysis.
130	To investigate the prevalence of EV-D68 in the cohort, two novel EV-D68 specific
131	primer combinations, amplifying the VP1 capsid gene, were utilized. An additional novel pan-
132	enterovirus specific control assay targeting the conserved 5' UTR region was also employed
133	(31).
134	Of these 194 EV clinical-assay-positive extracts, our study assays confirmed EV in 143
135	(73.7%). Of the confirmed EV positive samples, EV-D68 RNA was detected in 58.0% of cases
136	(n=83) as determined by sequencing of products from either or both VP1 study assays.
137	The diagnostic results for the 51 (26.3%) TNA extracts where EV RNA was not detected
138	by our in-house EV assays were reviewed. All had either a high ratio of combined RV/EV viral
139	load to EV specific viral load, indicating potential cross-reactivity with rhinoviruses in the EV
140	specific AusDiagnostics assays, three of which were confirmed by sequencing; or alternatively a
141	low EV value on initial screening, suggesting a low EV viral load in the original sample below
142	the lower limit of detection of the study assays or degradation of RNA within the TNA extract on
143	repeat freeze thaw.
144	Enterovirus D68 epidemiology, 2018 weeks 36 to 50
145	All amplicons were sequenced by Sanger and typed using the Genome Detective online
146	tool (33). A full VP1 sequence was amplified and used for subsequent phylogenetic analysis in
147	70 of 83 (84.3 %) samples but sequencing of a partial VP1 region in isolation still allowed for

148	successful subtyping. Co-circulation of two EV-D68 subclades was observed as reported
149	concurrently elsewhere in Europe (18-20), with 50 subclade B3 and 33 subclade D1 positives
150	identified (Figure 2). EV-D68 B3 predominated in the peak epidemic period of weeks 40 and 41,
151	whilst strains belonging to the less prevalent subclade D1 were present throughout the study
152	period, with peaks seen in weeks 38 and 43 (Figure 2).
153	Patients with EV-D68 B3 were significantly younger than those infected with subclade
154	D1 (p value = 0.0009, Table 1) with 64.0 % (n=32) of B3 positive patients ≤ 18 years of ages, and
155	78.1 % (n=25) of those patients under five years (figure 3). In contrast, 91% (n=30) of patients
156	with EV-D68 subclade D1 were >18 years, with the majority (75.6%, $n=25$) of patients aged 45
157	years and over (Figure 3).
158	Clinical features of EV-D68 positive patients
159	Detailed clinical information was available for 81 of 83 EV-D68 positive individuals and
160	analysis of a range of these features associated with either EV-D68 genotype D1 or genotype B3
161	was performed using binary logistic regression (Table 1). This regression model indicated that
162	greater age was associated with EV-D68 D1 infection, while immunocompromise significantly
163	associated with B3 infection. Overall, the model correctly predicted 85.19% of cases.
164	Respiratory symptoms were present for 91.4 % of patients, most commonly a cough (75.3%),
165	shortness of breath (56.8%), coryza (48.1%), wheeze and a requirement for oxygen (both
166	46.9%). Fever was also frequently reported (38.3%) as were co-morbidities (56.8%).
167	Neurological symptoms were reported in only four cases (4.9%), including two cases of AFM,
168	one in a young adult and the other in a 1-year old child. In both cases EV-D68 clade B3 was
169	detected; in the CSF of the adult and, unusually, in the faeces of the paediatric AFM case. No
170	other CSF or faecal samples in the study period were found to be EV-D68 positive. The adult

171 AFM patient required intensive care as did five other patients – another young adult and four 172 children aged 0-9 years. All five patients were infected with EV-D68 clade B3. 173 Genetic epidemiology of Enterovirus D68 in Nottingham, UK, between September and December 174 2018 To investigate the genetic relationship of the study EV-D68 strains, a phylogenetic tree 175 with our 70 complete VP1 sequences and the entire available global dataset of c.1500 sequences 176 177 (Supplementary Figure 1) was constructed. Clade D1 VP1 sequences presented as a closely related group within the total dataset (Figure 4), whilst B3 sequences were split across two 178 179 distinct phyletic groups (Figure 5 and 6). 180 The VP1 subtree harbouring all the D1 sequences from this study (Figure 4) was most closely out-grouped, yet distinct from, both prior-2016 isolates from East Asia (e.g. MH780679 181 182 and KY358058), a contemporary 2018 French sample (MK121713 (19)) and later-2019 isolates from Europe (e.g. LR743441 (17)). The subtree containing all 30 full-length VP1 D1 sequences 183 184 from this study and 39 database references could be subdivided into two further phyletic groups. 185 The first (Figure 4, lower half) contained exclusively contemporary European isolates from 186 investigations in France and Italy ((18, 19), whereas the other (Figure 4, upper half) additionally 187 contained a well-supported subgroup with four 2017 sequences from the USA and Hong Kong, a 2018 French isolate (MK121728 (19)) and a single Nottingham sequence. Interestingly, this 188 latter patient (NUH EVD68 60) was the only one in the cohort to report recent travel history to 189 190 East Asia. Our study sequences frequently shared a closer genetic relationship with 191 contemporary isolates from continental Europe than with each other. For example, samples NUH_EVD68_21, 23 & 25 were all sampled within 24 hours of each other, yet appeared in 192

discrete, well-supported regions of the tree with a closer genetic identity to various Europeanisolates than each other (Figure 4).

The Nottingham EV-D68 B3 sequences (Figures 5 and 6) presented a similar picture of co-mingling with contemporary European isolates, with for example NUH_EVD68_34 residing in a well-supported cluster of EV-D68 B3 sequences with three French and one Italian strain (Figure 6). Whereas the chronologically adjacent UK sequence NUH_EVD68_33 sampled on the previous day, appeared in an entirely different but equally well-supported sub-clade of B3 (Figure 5).

201 Recent travel history was also noted for other patients in both clades (NUH EVD68 4, 7, 202 20 & 27, Figures 4-6). Of note, NUH_EVD68_20 (Figure 6), with recent Spanish travel history, presented in a distinct supported phyletic group with four Chinese sequences from 2016 and 203 204 2017 (35). The other cases, with travel histories to the USA, Denmark and Spain did not present 205 any distinctive sub-groupings with reference sequences. However, NUH_EVD68_4 (Figure 6), 206 also with recent Spanish travel history, presented an identical VP1 sequence to NUH_EVD68_15 207 received 13 days later. Both these patients were 5 years old and shared the same hometown and outer UK postcode. There were eight other instances of identical pairs or clusters of study 208 sequences, but clinical details did not suggest a direct familial or geographical association. Most 209 210 were relatively closely sampled in time, but NUH_EVD68_35 and 65 were received two months apart in different but adjacent UK outer postcodes. 211

Taken together, these observations would suggest both Europe-wide and local circulation of multiple strains of both B3 and D1 clades underlying the Autumn 2018 EV-D68 epidemic.

214 Discussion

215	Enteroviruses can cause a wide range of severe clinical manifestations, notably in young
216	children and are a leading cause of meningitis globally (2). Continued surveillance of
217	enteroviruses within the UK despite the elimination of Polio is still highly relevant, notably
218	highlighted by the recent resurgence and recurrent epidemic seasonality of EV-D68 with
219	associated AFM globally and nationally in the UK (36-39).
220	Growing recognition of AFM and enteroviral association in Autumn 2018 prompted us to
221	further investigate enterovirus positive samples using novel in house RT-PCR assays and Sanger
222	sequencing. Whilst this approach is well established and more recently over-shadowed by whole
223	genome sequencing using deep sequencing methods, it provides a flexible, inexpensive and fast
224	route to enteroviral typing and epidemiology in a clinical setting.
225	We found a significant burden of EV-D68 infection in our 2018 study period between
226	September and December, coinciding with an overall increase in EV/RV positivity, responsible
227	for 58.0% of 143 confirmed enteroviral positives, over ten-fold higher than its overall recent EU
228	prevalence of 4.53% (2). It is difficult to determine the context of this spike in EV-D68 positivity
229	locally, relative to both the rest of 2018 and other years, without routine typing of all enterovirus
230	positive respiratory samples in addition to the more frequently assessed neurological symptom-
231	associated enteroviral infections (2, 26, 31, 40). EV-D68 is an endemic infection maintained in
232	the population and is still detected in Europe out of the currently expected biennial peak years
233	(17), but resources were not available to routinely type respiratory samples outside of our
234	focused study period.
235	We targeted the highly variable and type-indicative enteroviral VP1 region (26) with
236	novel primers specific to EV-D68 to not only discriminate EV-D68 infection (no cross-reactivity

237 was observed with other enteroviruses), but also determine the relative contribution by

238 circulating clades. To our knowledge, this allows us to present the largest fully typed EV-D68 239 cohort from a single centre and epidemic season. Whilst both clades were present throughout our 240 sampling period, an approximately 60:40 predominance of clade B3 relative to D1 was observed. 241 This was the reverse of clade prevalence seen in other European studies of the 2018 EV-D68 season in France (19) and Italy (18), but in agreement with other investigations of previous 242 seasons in France (20), Italy (21) and more generally in Europe post-2018 (17). 243 Universal typing and relatively large cohort size enabled us to investigate EV-D68 clade 244 245 association with clinical characteristics with more statistical power than most other studies to 246 date. Here we found a highly significant association between age and clade type, with clade B3 247 predominantly affecting children and adolescents, whilst conversely D1 was seen in older adults and the elderly. This finding is in agreement with previous observations (8, 19, 21), but only one 248 249 other study of sufficient size and scope to assign statistical significance (41). EV-D68 seroprevalence in adults is almost universal with primary infection seen 250 251 frequently in the first two years of life (23, 24). The predominance of the novel D1 clade in 252 hospitalized older adults may indicate an evolutionary adaptation of EV-D68 to evade a preexisting immune response and facilitate repeat infection. Recent and rapid evolution of antigenic 253 regions of the outer viral capsid corresponding to neutralizing epitopes has been suggested to be 254 255 implicated (8, 21, 41). Lineage specific protection determined by a primary infection influencing 256 virus-type age distribution has been described for several other viral infections, notably Influenza 257 A and B (42, 43).

Despite the significant differences in age profile for each clade and our cohort size, no difference was seen in clinical presentations recorded, in agreement with others (20). The general clinical picture of symptoms indicative of both upper and lower respiratory tract infections was

261 consistent with other studies (18, 19, 21, 28, 44). Although all severe cases, including those with 262 neurological involvement such as AFM, presented with clade B3, their infrequency prevents 263 robust analysis and all were in younger individuals shown to be more likely infected by clade 264 B3. Indeed AFM is not restricted to the B3 clade (4, 45, 46) and is perhaps more likely associated with the predominant local strain infecting a naïve population and overall infection 265 266 rates, rather than recently acquired properties as hypothesized by some (46) and thus not a 267 recently acquired phenotype (12). Perhaps more notable in both of the AFM cases was the infrequently reported viral 268 269 genome detection in CSF and faeces, with EV-D68 being a predominantly respiratory pathogen and thus typically detected by sampling the respiratory tract (2, 47). This finding supports a role 270 for viral replication disseminated from the respiratory tract in EV-D68-associated AFM, 271 although EV-D68 detection in sewage in the UK (48) and elsewhere (49) suggests faecal 272 273 shedding may not be an unusual feature of infection in general. 274 We observed a considerable genetic diversity within the VP1 regions of both the B3 and 275 D1 clades within our single epidemic season analysis, consistent and co-mingling with other 276 contemporary European cohorts (18, 19). In conjunction with the post-summer spike in case 277 incidence, this is suggestive of a high level of community infection seeded by many regional 278 and international introductions as described in more detail elsewhere (41) and foreshadowing SARS-CoV-2 pandemic dynamics (50). Our complete VP1 sequencing in conjunction with a 279 280 detailed clinical audit provides greater granularity than many other studies. Notably an individual with immediate East Asian travel history presented an EV-D68 VP1 sequence distinct from any 281 other European isolates recorded to date, suggesting direct intercontinental importation. Other 282

cases with recent summer travel history in Europe, combined with well-supported genetically

related sequences from both Europe and the immediate local neighbourhood, are anecdotally
suggestive of acquisition on holiday and onward transmission thereafter. Another case with
Spanish travel history clustered exclusively with sequences from previous years in China,
suggestive of considerable yet undetected intercontinental and international transmission chains
occurring.

However, with minimal global surveillance in comparison to that seen with SARS-CoV-2, assessing onward transmission from such introductions is difficult to definitely ascertain in the short term, with prevailing introductions apparent only in subsequent epidemic periods. Yet despite this lack of resolution, EV-D68 VP1 sequencing assured local infection control teams in retrospect that individuals sharing hospital wards did not harbour genetically identical viruses and thus nosocomial transmission was unlikely and infection prevention measures in place were effective.

We acknowledge several limitations in the work presented, principally the relatively short 296 297 single time-period assessed. Continuous and routine typing of all candidate EV positive 298 specimens received from an earlier outset would have provided a more complete picture and 299 understanding of the evolving local EV-D68 burden. We thus could not assign a start and end 300 point to our EV-D68 epidemic season. Recent initiatives such as the European non-polio enterovirus network (26, 36, 40) to which NUH NHS Trust Clinical Microbiology have 301 contributed, will undoubtedly assist in increasing such surveillance. Working retrospectively 302 303 with available diagnostic surplus further reduced both the sampling in the selected time period 304 and also generally meant only single patient samples were available, thus for example general faecal shedding from patients with respiratory symptoms could not be investigated. We also may 305 306 have overlooked some low titre EV-D68 positive patients by not re-screening routine diagnostic

307	assay negative samples. Sub-optimal performance in diagnosing EV-D68 and other EV by our
308	chosen routine diagnostic assay and others has indeed been observed (40).
309	In summary, EV-D68 contributed significantly to the burden of enteroviral respiratory

- disease treated at our regional UK hospital between September and December 2018. Underlying
- this period of high prevalence were genetically distinct strains of clade B3 and D1 EV-D68,
- which differed in their infected host's age group, but not in clinical presentation. Despite
- considerable contemporary concern and focus on the severe associated outcomes of EV-D68
- infection, ultimately confirmed AFM cases were rare even in this largely hospitalized cohort.
- Nevertheless, the apparently increasing burden of EV-D68 and diverse, rapidly evolving genome
- demands continued heightened surveillance.

317 Acknowledgments

- None to report
- 319 Disclaimers
- 320 None to report
- 321 Funding
- 322 No external funding was received for this study.

323 **Conflicts of interest**

The authors have no relevant conflicts as outlined by the ICMJE to declare.

325 **References**

- 1. Simmonds P, Gorbalenya AE, Harvala H, Hovi T, Knowles NJ, Lindberg AM, et al.
- Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch Virol.
- 328 2020 Mar;165(3):793-7.

329	2.	Bubba L, Broberg EK, Jasir A, Simmonds P, Harvala H, Enterovirus study c. Circulation
330		of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a
331		retrospective surveillance study. Lancet Infect Dis. 2019 Dec 20.
332	3.	Pons-Salort M, Grassly NC. Serotype-specific immunity explains the incidence of
333		diseases caused by human enteroviruses. Science. 2018 Aug 24;361(6404):800-3.
334	4.	Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, et al. A novel
335		outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA
336		(2012-14): a retrospective cohort study. Lancet Infect Dis. 2015 Jun;15(6):671-82.
337	5.	Eshaghi A, Duvvuri VR, Isabel S, Banh P, Li A, Peci A, et al. Global Distribution and
338		Evolutionary History of Enterovirus D68, with Emphasis on the 2014 Outbreak in
339		Ontario, Canada. Front Microbiol. 2017;8:257.
340	6.	Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, et al. A
341		cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with
342		an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015 Apr
343		25;385(9978):1662-71.
344	7.	Kirolos A, Mark K, Shetty J, Chinchankar N, McDougall C, Eunson P, et al. Outcome of
345		paediatric acute flaccid myelitis associated with enterovirus D68: a case series. Dev Med
346		Child Neurol. 2019 Mar;61(3):376-80.
347	8.	Lau SK, Yip CC, Zhao PS, Chow WN, To KK, Wu AK, et al. Enterovirus D68 Infections
348		Associated with Severe Respiratory Illness in Elderly Patients and Emergence of a Novel
349		Clade in Hong Kong. Sci Rep. 2016 Apr 28;6:25147.

350	9.	Gong YN, Yang SL, Shih SR, Huang YC, Chang PY, Huang CG, et al. Molecular
351		evolution and the global reemergence of enterovirus D68 by genome-wide analysis.
352		Medicine (Baltimore). 2016 Aug;95(31):e4416.
353	10.	Hixon AM, Yu G, Leser JS, Yagi S, Clarke P, Chiu CY, et al. A mouse model of
354		paralytic myelitis caused by enterovirus D68. PLoS Pathog. 2017 Feb;13(2):e1006199.
355	11.	Brown DM, Hixon AM, Oldfield LM, Zhang Y, Novotny M, Wang W, et al.
356		Contemporary Circulating Enterovirus D68 Strains Have Acquired the Capacity for Viral
357		Entry and Replication in Human Neuronal Cells. mBio. 2018 Oct 16;9(5).
358	12.	Rosenfeld AB, Warren AL, Racaniello VR. Neurotropism of Enterovirus D68 Isolates Is
359		Independent of Sialic Acid and Is Not a Recently Acquired Phenotype. mBio. 2019 Oct
360		22;10(5).
361	13.	Vogt MR, Crowe JE, Jr. Current Understanding of Humoral Immunity to Enterovirus
362		D68. J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S49-S53.
363	14.	Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, et al.
364		Enterovirus 68 is associated with respiratory illness and shares biological features with
365		both the enteroviruses and the rhinoviruses. J Gen Virol. 2004 Sep;85(Pt 9):2577-84.
366	15.	Levy A, Roberts J, Lang J, Tempone S, Kesson A, Dofai A, et al. Enterovirus D68
367		disease and molecular epidemiology in Australia. J Clin Virol. 2015 Aug;69:117-21.
368	16.	Foster CB, Friedman N, Carl J, Piedimonte G. Enterovirus D68: a clinically important
369		respiratory enterovirus. Cleve Clin J Med. 2015 Jan;82(1):26-31.
370	17.	Midgley SE, Benschop K, Dyrdak R, Mirand A, Bailly JL, Bierbaum S, et al. Co-
371		circulation of multiple enterovirus D68 subclades, including a novel B3 cluster, across
372		Europe in a season of expected low prevalence, 2019/20. Euro Surveill. 2020 Jan;25(2).

373	18.	Pellegrinelli L, Giardina F, Lunghi G, Uceda Renteria SC, Greco L, Fratini A, et al.
374		Emergence of divergent enterovirus (EV) D68 sub-clade D1 strains, northern Italy,
375		September to October 2018. Euro Surveill. 2019 Feb;24(7).
376	19.	Bal A, Sabatier M, Wirth T, Coste-Burel M, Lazrek M, Stefic K, et al. Emergence of
377		enterovirus D68 clade D1, France, August to November 2018. Euro Surveill. 2019
378		Jan;24(3).
379	20.	Kramer R, Sabatier M, Wirth T, Pichon M, Lina B, Schuffenecker I, et al. Molecular
380		diversity and biennial circulation of enterovirus D68: a systematic screening study in
381		Lyon, France, 2010 to 2016. Euro Surveill. 2018 Sep;23(37).
382	21.	Piralla A, Principi N, Ruggiero L, Girello A, Giardina F, De Sando E, et al. Enterovirus-
383		D68 (EV-D68) in pediatric patients with respiratory infection: The circulation of a new
384		B3 clade in Italy. J Clin Virol. 2018 Feb - Mar;99-100:91-6.
385	22.	Duval M, Mirand A, Lesens O, Bay JO, Caillaud D, Gallot D, et al. Retrospective Study
386		of the Upsurge of Enterovirus D68 Clade D1 among Adults (2014-2018). Viruses. 2021
387		Aug 13;13(8).
388	23.	Kamau E, Harvala H, Blomqvist S, Nguyen D, Horby P, Pebody R, et al. Increase in
389		Enterovirus D68 Infections in Young Children, United Kingdom, 2006-2016. Emerg
390		Infect Dis. 2019 Jun;25(6):1200-3.
391	24.	Harrison CJ, Weldon WC, Pahud BA, Jackson MA, Oberste MS, Selvarangan R.
392		Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014
393		Outbreak, Kansas City, Missouri, USA(1). Emerg Infect Dis. 2019 Mar;25(3):585-8.

394	25.	Mishra N, Ng TFF, Marine RL, Jain K, Ng J, Thakkar R, et al. Antibodies to
395		Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis. mBio. 2019
396		Aug 13;10(4).
397	26.	Harvala H, Broberg E, Benschop K, Berginc N, Ladhani S, Susi P, et al.
398		Recommendations for enterovirus diagnostics and characterisation within and beyond
399		Europe. J Clin Virol. 2018 Apr;101:11-7.
400	27.	Bowers JR, Valentine M, Harrison V, Fofanov VY, Gillece J, Delisle J, et al. Genomic
401		Analyses of Acute Flaccid Myelitis Cases among a Cluster in Arizona Provide Further
402		Evidence of Enterovirus D68 Role. mBio. 2019 Jan 22;10(1).
403	28.	Wang H, Diaz A, Moyer K, Mele-Casas M, Ara-Montojo MF, Torrus I, et al. Molecular
404		and Clinical Comparison of Enterovirus D68 Outbreaks among Hospitalized Children,
405		Ohio, USA, 2014 and 2018. Emerg Infect Dis. 2019 Nov;25(11):2055-63.
406	29.	Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1
407		sequences for direct identification of all enterovirus serotypes from original clinical
408		specimens. J Clin Microbiol. 2006 Aug;44(8):2698-704.
409	30.	Simmonds P, Welch J. Frequency and dynamics of recombination within different
410		species of human enteroviruses. J Virol. 2006 Jan;80(1):483-93.
411	31.	Howson-Wells HC, Winckles S, Aliker C, Tarr AW, Irving WL, Clark G, et al.
412		Enterovirus subtyping in a routine UK laboratory setting between 2013 and 2017. J Clin
413		Virol. 2020 Nov;132:104646.
414	32.	Dierssen U, Rehren F, Henke-Gendo C, Harste G, Heim A. Rapid routine detection of
415		enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay. J Clin
416		Virol. 2008 May;42(1):58-64.

417	33.	Kroneman A, Vennema H, Deforche K, v d Avoort H, Penaranda S, Oberste MS, et al.
418		An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol. 2011
419		Jun;51(2):121-5.
420	34.	Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et
421		al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the
422		Genomic Era. Mol Biol Evol. 2020 May 1;37(5):1530-4.
423	35.	Tang SH, Yuan Y, Xie ZH, Chen MJ, Fan XD, Guo YH, et al. Enterovirus D68 in
424		hospitalized children with respiratory symptoms in Guangdong from 2014 to 2018:
425		Molecular epidemiology and clinical characteristics. J Clin Virol. 2021 Aug;141:104880.
426	36.	Fischer TK, Simmonds P, Harvala H. The importance of enterovirus surveillance in a
427		post-polio world. Lancet Infect Dis. 2021 Jul 12.
428	37.	Carrion Martin AI, Pebody RG, Danis K, Ellis J, Niazi S, S DEL, et al. The emergence of
429		enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus
430		respiratory screening. Epidemiol Infect. 2017 Jul;145(9):1855-64.
431	38.	Park SW, Pons-Salort M, Messacar K, Cook C, Meyers L, Farrar J, et al. Epidemiological
432		dynamics of enterovirus D68 in the United States and implications for acute flaccid
433		myelitis. Sci Transl Med. 2021 Mar 10;13(584).
434	39.	The United Kingdom Acute Flaccid Paralysis Afp Task F. An increase in reports of acute
435		flaccid paralysis (AFP) in the United Kingdom, 1 January 2018-21 January 2019: early
436		findings. Euro Surveill. 2019 Feb;24(6).
437	40.	Hayes A, Nguyen D, Andersson M, Anton A, Bailly JL, Beard S, et al. A European
438		multicentre evaluation of detection and typing methods for human enteroviruses and
439		parechoviruses using RNA transcripts. J Med Virol. 2019 Dec 28.

440	41.	Hodcroft EB, Dyrdak R, Andrés C, Egli A, Reist J, García Martínez de Artola D, et al.
441		Evolution, geographic spreading, and demographic distribution of Enterovirus D68.
442		bioRxiv. 2020:2020.01.10.901553.
443	42.	Vieira MC, Donato CM, Arevalo P, Rimmelzwaan GF, Wood T, Lopez L, et al. Lineage-
444		specific protection and immune imprinting shape the age distributions of influenza B
445		cases. Nat Commun. 2021 Jul 14;12(1):4313.
446	43.	Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1
447		and H7N9 influenza via childhood hemagglutinin imprinting. Science. 2016 Nov
448		11;354(6313):722-6.
449	44.	Schuster JE, Selvarangan R, Hassan F, Briggs KB, Hays L, Miller JO, et al. Clinical
450		Course of Enterovirus D68 in Hospitalized Children. Pediatr Infect Dis J. 2017
451		Mar;36(3):290-5.
452	45.	Kaida A, Iritani N, Yamamoto SP, Kanbayashi D, Hirai Y, Togawa M, et al. Distinct
453		genetic clades of enterovirus D68 detected in 2010, 2013, and 2015 in Osaka City, Japan.
454		PLoS One. 2017;12(9):e0184335.
455	46.	Zhang Y, Cao J, Zhang S, Lee AJ, Sun G, Larsen CN, et al. Genetic changes found in a
456		distinct clade of Enterovirus D68 associated with paralysis during the 2014 outbreak.
457		Virus Evol. 2016 Jan;2(1):vew015.
458	47.	Chong PF, Kira R, Mori H, Okumura A, Torisu H, Yasumoto S, et al. Clinical Features
459		of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak:
460		Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December
461		2015. Clin Infect Dis. 2018 Feb 10;66(5):653-64.

- 462 48. Majumdar M, Martin J. Detection by Direct Next Generation Sequencing Analysis of
- 463 Emerging Enterovirus D68 and C109 Strains in an Environmental Sample From
- 464 Scotland. Front Microbiol. 2018;9:1956.
- 465 49. Weil M, Mandelboim M, Mendelson E, Manor Y, Shulman L, Ram D, et al. Human
- 466 enterovirus D68 in clinical and sewage samples in Israel. J Clin Virol. 2017 Jan;86:52-5.
- 467 50. du Plessis L, McCrone JT, Zarebski AE, Hill V, Ruis C, Gutierrez B, et al. Establishment
- and lineage dynamics of the SARS-CoV-2 epidemic in the UK. Science. 2021 Feb
- 469 12;371(6530):708-12.
- 470 Tables
- 471 Table 1. Clinical features of EV-D68 patients, Nottingham, UK, Autumn 2018

Characteristic	All EV-D68		EV-D68 B3		EV-D68 D1		Odds ratio range	95% Cl p val		ue
Age range	23 days to 92 years		23 days to 92 years (median 4.5 years)		8 months to 89 years (median 56 years)		1.1	1.037 to 1.136	0.000 9	***
	n	%	п	%	п	%				
Female gender	44	54.3	24	48	20	64.5	0.5	0.092 to 2.124	0.310 1	ns
Respiratory symptoms	74	91.4	46	92	28	90.3	1.1	0.068 to 19.91	0.928	ns
Cough	61	75.3	37	74	24	77.4	4.1	0.502 to 37.37	0.188 5	ns
Shortness of breath	46	56.8	29	58	17	54.8	2.2	0.422 to 13.05	0.347 8	ns
Coryza	39	48.1	29	58	10	32.3	0.9	0.181 to 4.801	0.945 7	ns
Wheeze	38	46.9	28	56	10	32.3	7.0	1.022 to 67.29	0.062	ns
Oxygen	38	46.9	25	50	13	41.9	0.4	0.069 to 2.231	0.314 3	ns
Sore throat	8	9.9	4	8	4	12.9	4.9	0.482 to 66.36	0.193	ns
Bronchiolitis	8	9.9	6	12	2	6.5	12.6	0.941 to 207.0	0.055 4	ns
Pneumonia	7	8.6	1	2	6	19.4	1.7	0.098 to 67.89	0.724 2	ns
Fever	31	38.3	19	38	12	38.7	0.6	0.124 to 2.928	0.550 2	ns
Suspected sepsis	7	8.6	5	10	2	6.5	0.0	0.0005 to 1.100	0.078 9	ns
Co-morbidities	46	56.8	23	46	23	74.2	3.1	0.627 to 19.11	0.183 8	ns
Neurological	4	4.9	3	6	1	3.2	0.8	0.017 to	0.878	ns

symptoms								19.74		
Immunocompromi sed	14	17.3	9	18	5	16.1	0.1	0.004 to 0.4574	0.015 5	*
Total	81		50		31					
Clinical parameters were determined from existing clinical records on each patient. Data with continuous variables, and categorical										
variables (including comorbidities, presence of fever, presence of neurological symptoms, and previous evidence of										
immunocompromise) were included in a binary logistic regression model. ns = non-significant, CI = confidence interval										

473 **Figure Legends**

474 Figure 1: The number of respiratory specimens from which rhinovirus/enterovirus (RV/EV) and

enterovirus (EV; species A-D) were detected between 2018 week 32 and 2019 week 3, as

476 reported by NUH NHS Trust, Nottingham, UK. TNA from samples received from weeks 36 to

477 50 (marked by dashed lines) were subjected to further analysis.

478

472

Figure 2: EV-D68 prevalence by individual patient and clade, from weeks 36 to 50 of 2018 at
NUH NHS Trust, Nottingham UK.

481

Figure 3: Age distribution of patients infected with EV-D68, stratified by subclade (B3 and D1).

484 Figure 4: Phylogenetic relationship by maximum likelihood method of Nottingham, UK, 2018

485 complete EV-D68 VP1 sequences (927-930 bp) designated genotype D1 (colored in red) with all

486 closely related publically available genomes retrieved from Genbank in June 2021 (identified by

487 accession number). The phylogeny depicted is a subtree of a complete tree with entire study and

- 488 global sequence dataset presented in the appendix (Supplementary Figure 1). Numbers above
- individual branches indicate SH-aLRT bootstrap support, with values less than 70 not shown.
- 490 Branch lengths are drawn to a scale of nucleotide substitutions per site, with scale indicated.

491

Figure 5: Phylogenetic relationship by maximum likelihood method of Nottingham, UK, 2018
complete EV-D68 VP1 sequences (927-930 bp) designated genotype B3, subgroup 1 (coloured
in red) with all closely related publically available genomes retrieved from Genbank in June
2021 (identified by accession number). The phylogeny depicted is a subtree of a complete tree
with entire study and global sequence dataset presented in the appendix (Supplementary Figure
1). Numbers above individual branches indicate SH-aLRT bootstrap support, with values less
than 70 not shown. Branch lengths are drawn to a scale of nucleotide substitutions per site, with

499 scale indicated.

500

Figure 6: Phylogenetic relationship by maximum likelihood method of Nottingham, UK, 2018 501 complete EV-D68 VP1 sequences (927-930 bp) designated genotype B3, subgroup 2 (coloured 502 503 in red) with all closely related publically available genomes retrieved from Genbank in June 504 2021 (identified by accession number). The phylogeny depicted is a subtree of a complete tree 505 with entire study and global sequence dataset presented in the appendix (Supplementary Figure 506 1), with well supported branches containing no study sequences collapsed to improve clarity. Numbers above individual branches indicate SH-aLRT bootstrap support, with values less than 507 70 not shown. Branch lengths are drawn to a scale of nucleotide substitutions per site, with scale 508 509 indicated.

510

Supplementary Figure 1. Phylogenetic relationship by maximum likelihood method of
Nottingham, UK, 2018 complete EV-D68 VP1 sequences (927-930 bp, coloured in red) with all
publically available genomes retrieved from Genbank in June 2021 (identified by accession
number). Position of subtrees presented as figures 4 - 6 in main text is annotated. SH-aLRT

- 515 bootstrap support values have been omitted for clarity. Branch lengths are drawn to a scale of
- 516 nucleotide substitutions per site, with scale indicated.



■ RV / EV ■ EV



9 -

■ EV-D68 B3 ■ EV-D68 D1



■ EV-D68 D1 ■ EV-D68 B3





74.7



NUH_EVD68_70/Nottingham/2018

78.2 MN726798.1 MN894273.1 MK301343.1 MK301345.1 MK301349.1 MK121728.1 NUH_EVD68_66/Nottingham/2018 NUH_EVD68_68/Nottingham/2018 NUH_EVD68_11/Nottingham/2018 NUH_EVD68_25/Nottingham/2018

MK301352.1





MN894274.1 MN809623.1 MN246003.1

MK659600.1 MN246001.1 MK659597.1

> 93.4 MT081368.1 MN246035.1 MK659588.1 MN245987.1

MK659599.1 MK659593.1

MT789746.1

MK121711.1

MK301351.1

MK301353.1

